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ABSTRACT
Three dogs were investigated for chronic unilateral nasal discharge. In all cases CT imaging
showed an intranasal mass causing turbinate lysis and no evidence of metastasis. Cytology in
cases 1 (a 14-year-old neutered male crossbreed dog) and 2 (a ﬁve-year-old neutered male
German Shepherd dog) demonstrated a pleomorphic cell population with variable intracellular
pigment suspicious of melanocytic neoplasia. Histopathology with immunohistochemistry
(Melan-A and vimentin, plus PNL-2 in one case) conﬁrmed the diagnosis of melanoma in all
dogs. All dogs were treated with megavoltage radiotherapy using linear accelerators. Cases 1
and 3 (a nine-year-old neutered female beagle dog) received a hypofractionated (4 £ 8 Gy)
protocol and case 2 received a deﬁnitive (12 £ 4 Gy) protocol. Complete remission was
demonstrated on repeat CT scan ﬁve months after diagnosis in case 1 and seven months in
case 2. Stable disease was documented on CT at four months for case 3; however, clinical signs
in this dog remained controlled for 10 months in total. Case 1 died of unrelated causes ﬁve
months after diagnosis, case 2 was euthanased due to the development of seizures 13 months
after diagnosis, and case 3 was lost to follow-up 12 months after diagnosis. Melanoma should
be considered as a rare differential diagnosis for primary nasal neoplasia in the dog and
radiation therapy can be used as effective local therapy.
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1. Introduction
Most intranasal neoplasms in the dog are carcinomas
and sarcomas (Madewell et al. 1976; Kubicek et al.
2016) and rarely other tumours, including lymphoma
(Patnaik 1989), mast cell tumours (Naganobu et al.
2000), transmissible venereal tumours (Papazoglou
et al. 2001), haemangiosarcoma (Fujita et al. 2008),
neuroblastoma (Ueno et al. 2007) and multilobular
osteochondrosarcoma (Patnaik 1989) have been
reported. The primary treatment of most canine intra-
nasal neoplasms is radiotherapy (Lana et al. 2004; Law-
rence et al. 2010) often with adjuvant chemotherapy
(Lana et al. 2004; Adams et al. 2005). Neoadjuvant sur-
gical debulking has also been described, but has not
been shown to improve clinical outcome (Morris et al.
1994; Adams et al. 2005).
Most intranasal cancers in humans are squamous
cell carcinomas (Peryaga et al. 2016). Primary intranasal
melanoma is uncommon, accounting for approxi-
mately 3.6% of all nasal tumours in people (Gouldes-
brough et al. 1992). Treatment typically involves radical
surgery and adjunctive radiotherapy (Lin et al. 2003).
Intranasal melanoma in the dog is considered excep-
tionally rare, with one case report in the literature
describing a dog treated with surgical debulking (via
rhinotomy) and adjunctive radiotherapy (Hicks & Fidel
2006).
Canine melanoma typically occurs in the oral cavity,
lip, haired skin and digits, with other sites constituting
2% of the total (Smith et al. 2002). Melanomas originat-
ing from mucous membranes, speciﬁcally oral, are usu-
ally associated with invasive behaviour and a high
metastatic rate (Millanta et al. 2002). Local control is
achieved with radical surgery or hypofractionated radio-
therapy. However, most dogs will die or be euthanased
as a result of metastatic disease (Tuohy et al. 2014).
This report describes three cases of canine intrana-
sal melanoma treated with radiotherapy.
2. Case series
2.1. Case 1
Case 1 was a 14-year-old neutered male, 23.5 kg cross-
breed dog, presented for evaluation of a ﬁve-month
history of sneezing and muco-haemorrhagic, right-
sided nasal discharge. Physical examination revealed
reduced airﬂow through the right naris but was other-
wise unremarkable. A complete blood count, serum
biochemistry panel and cytology of both mandibular
lymph nodes were unremarkable.
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Contrast computed tomography (CT) of the head,
neck, thorax and abdomen was performed under gen-
eral anaesthesia. A soft tissue attenuating mass was
present in the right nasal cavity (measuring approxi-
mately 4.8 cm rostrocaudally, 1.7 cm dorsoventrally
and 1.9 cm lateromedially), associated with signiﬁcant
turbinate lysis and focal destruction of the right naso-
maxillary suture (Figure 1). No metastatic lesions were
identiﬁed. Rhinoscopy was used to obtain biopsy and
cytology samples.
Cytology of the nasal mass demonstrated a popula-
tion of pleomorphic polyhedral to spindloid cells
(Figure 2(a,b)). Nuclei were centrally placed and round
with stippled chromatin and one or multiple promi-
nent nucleoli; occasional macronuclei or multinucleate
cells were observed. The cellular pleomorphism and
presence of green pigment in some cells were sugges-
tive of a melanoma. Histopathology described pleo-
morphic, round to polygonal cells containing varying
numbers of nuclei, abundant eosinophilic cytoplasm
Figure 1. Pre-treatment and post-treatment CT images of case 1: (a) pre-treatment transverse; (b) post-treatment transverse; (c)
pre-treatment longitudinal; (d) post-treatment longitudinal. Arrows mark the location of the tumour.
Figure 2. Cytology from case 1: (a) multinucleate cells (black arrows) with variable pigmentation (red arrow); (b) a high degree of
cellular pigment (red arrow) and the marked pleomorphism (white arrows).
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with light-brown intracellular granules, and fewer than
one mitosis in 10 high-power (£ 400) ﬁelds. The histo-
genesis of the tumour was unclear; melanoma, olfac-
tory neuroblastoma, neuroendocrine tumour and
undifferentiated carcinoma were considered differen-
tial diagnoses. Fontana–Masson stain for melanin gran-
ules was weakly positive. Immunohistochemical
labelling (Table 1) showed the neoplastic cells to stain
strongly positive for melanocytic antigen recognized
by cytotoxic T lymphocytes (Melan-A), vimentin and
anti-melanoma antibody (PNL-2), and negative for
S100 protein, smooth muscle actin (SMA) and multiple
myeloma-1 protein (MUM-1), consistent with the diag-
nosis of melanoma (Busam & Jungbluth 1999; Ramos-
Vara & Miller 2011).
The dog was treated with a hypofractionated radio-
therapy protocol using a Varian 6MV ‘Clinac’ linear
accelerator and CT-based computer planning was per-
formed with CadPlan 3.0 software (version 1.3, Varian-
Dosetek, Palo Alto, CA, USA). The dog received general
anaesthesia for each fraction (premedicated with
0.2 mg/kg BW butorphanol intravenously, induced
with a total dose of 2.4 mg/kg BW propofol, given
intravenously ‘to effect’, maintained with isoﬂuorane in
100% oxygen via endotracheal tube). Positioning was
facilitated using a bespoke mouth-gag, and a combina-
tion of polystyrene blocks and tape. A total dose of 32
Gray (Gy; 1 joule of radiation energy absorbed per kilo-
gram of BW) was delivered to the tumour as four,
once-weekly 8 Gy fractions. A single radiation beam
was used; ﬁeld depth was 98.5 cm, clinical target vol-
ume (CTV) was 0.6 cm around the gross tumour vol-
ume (GTV), and the planning target volume (PTV) was
1.0 cm around CTV; eyes and brain were not included
in the treatment ﬁeld. Lymph nodes were not treated.
This treatment was tolerated with no apparent adverse
effects and resulted in rapid and complete resolution
of clinical signs. Repeat CT 4 months after treatment
demonstrated complete response of the nasal tumour
(Figure 1) and no evidence of metastatic disease. No
medical therapy was given. The dog was euthanased
due to discomfort associated with a soft tissue sarcoma
in its hind leg ﬁve months after diagnosis; CT scan at
this time revealed no metastatic disease from either
neoplasm, and the diagnosis of soft tissue sarcoma
was conﬁrmed on immunohistochemistry (negative
labelling for Melan-A, positive for vimentin). Necropsy
was not performed.
2.2. Case 2
Case 2 was a ﬁve-year-old neutered male, 44 kg Ger-
man Shepherd dog, presented for a three-week history
of intermittent left-sided muco-haemorrhagic, nasal
discharge and sneezing. Physical examination revealed
reduction in left-sided nasal airﬂow and mild left man-
dibular lymphadenomegaly. Complete blood count,
serum biochemistry, urinalysis, activated thromboplas-
tin and prothrombin times, and blood pressure were
within normal limits. Cytology of both mandibular
lymph nodes was unremarkable.
CT scan of the head, thorax and abdomen demon-
strated a large, contrast-enhancing soft tissue lesion in
the left nasal cavity (measuring approximately 6.4 cm
rostrocaudally, 2.7 cm dorsoventrally and 2.4 cm latero-
medially), causing signiﬁcant turbinate lysis and focal
Table 1. Immunohistochemical markers used in the diagnosis of Cases 1 and 2 in relation to published levels of expression in
canine melanoma. Primary and secondary antibodies used in the immunhositochemical labelling are given in brackets (1Ramos-
Vara et al. 2000; 2Giudice et al. 2010; 3Koenig et al. 2001; 4Rabanal et al. 1989).
Immunohistochemical
Marker Melanoma Case 1 (antibodies used) Case 2 (antibodies used)
Vimentin >95% tumours
positive3,4
Positive (1: Clone V9 mouse monoclonal anti-; Dako, Agilent.
2 : Dako Flex Kit)
Positive (1 : Clone V9 mouse monoclonal
anti-; Dako, Agilent. 2 : Dako Flex Kit)
Cytokeratin Negative4 Negative (1 : Clone 34bE12 mouse monoclonal anti-human;
Leica Biosystems. 2 : Leica Bond System)
Not assessed
Melan-A 59% tumours
positive2
Positive (1: Clone A103, mouse monoclonal anti-human;
Novocastra, Leica Biosystems. 2 : Leica Bond System)
Positive (1 : Clone A103 mouse
monoclonal anti-human; Dako, Agilent.
2: Dako Flex Kit)
PNL-2 62% tumours
positive2
Positive (1: Clone HMB45 mouse monoclonal; Santa Cruz
Biotechnology. 2: mouse IgG kappa binding protein,
conjugated to horseradish peroxidase, Santa Cruz)
Not assessed
S-100 76% tumours
positive1,3,4
Negative (1 : Puriﬁed rabbit polyclonal; Novocastra, Leica
Biosystems. 2 : Leica Bond System)
Not assessed
SMA Not known Negative (1 : Clone asm-1, mouse monoclonal anti-human;
Novocastra, Leica Biosystems. 2 : Leica Bond System)
Negative (1 : Clone 1A4 mouse
monoclonal anti-human; Dako, Agilent.
2: Dako Flex Kit)
MUM-1 Not known Negative (1 : Clone MUM1p, mouse monoclonal anti-human;
Dako, Agilent. 2 : Dako Flex Kit)
Not assessed
Desmin Negative4 Not assessed Negative (1 : Clone D33 mouse
monoclonal anti-human; Dako, Agilent.
2: Dako Flex Kit)
Neuron-speciﬁc enolase
(NSE)
59% tumours
positive3
Not assessed Negative (1 : Clone BBS/NC/VI-H14
mouse monoclonal anti-human; Dako,
Agilent. 2 : Dako Flex Kit)
Glial ﬁbrillary acidic
protein (GFAP)
Not known Not assessed Negative (1 : Polyclonal rabbit anti-;
Dako, Agilent. 2: Dako Flex Kit)
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destruction of the left nasomaxilliary bones (Figure 3).
No evidence of detectable metastasis was identiﬁed.
Cytology and biopsy samples were obtained via
rhinoscopy.
Cytology showed round to spindle-shaped cells
with moderate anisocytosis and anisokaryosis, and var-
iable nucleolar number and morphology. Dark pigment
was occasionally seen within these cells and melanoma
was deemed the most likely diagnosis. Histopathology
(Figure 1) was consistent with a poorly differentiated,
non-pigmented spindle cell malignancy. Mitotic activ-
ity was 0–2 per £400 ﬁeld. Immunohistochemical
labelling with vimentin, SMA, desmin, neuron-speciﬁc
enolase, glial ﬁbrillary acidic protein and melan-A was
performed. Neoplastic cells labelled with vimentin and
melan A, supporting the diagnosis of amelanotic mela-
noma (Figure 4(b,c), Table 1).
The dog was treated with a deﬁnitive radiotherapy
protocol directed to the primary tumour and mandibu-
lar lymph nodes. For planning CT and treatment deliv-
ery, the patient was placed under general anaesthesia,
(premedicated with intravenous medetomidine [5 ug/
kg BW] and butorphanol [0.015–0.03 mg/kg BW], or
medetomidine [7–10 ug/kg BW] alone for later frac-
tions, induced with propofol, maintained with sevoﬂur-
ane in 100% oxygen via endotracheal tube) and
positioned in sternal recumbency. Immobilization was
achieved using a thermoplastic mask and a customized
head support, secured to a plastic head-frame with
four points of ﬁxation. Radiotherapy consisted of 12
fractions of 4 Gy on a Monday, Wednesday, Friday basis
(48 Gy total), delivered using a Dual Energy Linear
Accelerator (Clinac 2100 C, Varian, Palo Alto, CA, USA)
with 0.5-cm multi-leaf collimator (MLC). All treatments
were carried out at 6 MV, and were 3D planned from
CT using Pinnacle (version 9), with beam collimation
using MLC and beam modiﬁcation using dynamic
wedges. Planning was carried out with the intent to
include 95% of the PTV (GTV plus 1–2 cm normal tissue
for CTV, planning treatment volume based on clinical
target volume plus 5 mm, adjusting ﬁnal planned treat-
ment volume margins manually to spare left eye and
reduce dose to brain tissue) in the 95%–105% iso-dose,
i.e. scheduled dose heterogeneity less than 15%. The
primary tumour was treated with three coplanar beams
(left lateral oblique 254; dorsoventral 356 with
dynamic wedge; ventrodorsal oblique 160 with
dynamic wedge). The submandibular lymph nodes
were treated with a separate two ﬁeld plan (left lateral
273; right lateral 83). Portal imaging was carried out
twice during the treatment protocol to verify position:
no adjustments were required. The lymph nodes were
irradiated as per the institutional policy for malignant
melanoma. In terms of organs at risk, the maximum
Figure 3. Pre-treatment and post-treatment CT images of case 2: (a) pre-treatment transverse; (b) post-treatment transverse; (c)
pre-treatment longitudinal; (d) post-treatment longitudinal. Arrows mark the location of the tumour.
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dose to the frontal lobes was 4740 centiGray (cGy):
these were not contoured separately from the brain.
For the whole brain, the minimum dose was 64 cGy,
and the mean 871 cGy. The mean dose to proximal
cord was 93 cGy, minimum 14 cGy, maximum 368 cGy.
The mean dose for the right eye was 4724 cGy, mini-
mum 3476 cGy, maximum 4878 cGy. The mean dose
for the left eye was 2076 cGy, minimum 1334 cGy, max-
imum 4413 cGy.
Concurrent prednisolone at 0.5 mg/kg BW orally,
once daily was administered for anti-inﬂammatory
effect. During the third week of radiation therapy con-
junctivitis in the left eye was noted; facial nerve func-
tion was normal and initially ﬂuorescein uptake of the
left cornea was negative. Two weeks later a Schirmer
tear test demonstrated low tear production in the left
eye (10 mm) however ﬂuorescein uptake remained
negative; oral prednisolone was reduced, topical ketor-
olac (Allergan Pharmaceuticals Ireland, Westport,
County Mayo, Ireland) and lubrication were introduced,
and a buster collar was placed to stop the dog trauma-
tizing the eye. Two weeks following, however, a deep
ulcer was noted. Enucleation was elected over other
treatments by the owners due to dog’s acute
discomfort.
Clinical signs of nasal discharge completely resolved
within four weeks of starting radiotherapy. Seven
months after diagnosis, a repeat CT scan of the head,
thorax and abdomen showed complete remission of
the nasal tumour; mucosal thickening and a small
amount of ﬂuid was present within the nasal cavity,
but no contrast-uptake was seen, consistent with a
complete response to therapy (Figure 3). No evidence
of metastatic disease was seen. At this point, ﬁrocoxib
(Previcox, Merial, Lyon, France) at 5 mg/kg BW orally,
once-daily, was prescribed to for potential anti-cancer
effect as a COX-2 inhibitor (Proulx et al. 2003; Martinez
et al. 2011). The ﬁrocoxib therapy was continued for
ﬁve months and clinically no adverse effects of treat-
ment were observed; supportive treatment (for exam-
ple, gastroprotectants) was therefore not considered
necessary. The dog developed seizure activity 13
months after diagnosis and was euthanized after fur-
ther investigations were declined. Necropsy was not
performed, and the aetiology of the seizures remains
unclear.
2.3. Case 3
Case 3 was a nine year-old neutered female, 17.1 kg
beagle dog with a four-week history of sneezing and
left-sided haemorrhagic nasal discharge. Physical
examination, a complete blood count and serum bio-
chemistry panel were unremarkable. Blind nasal biop-
sies had been performed by the referring veterinary
surgeon and histopathology demonstrated a diffuse
cellular proliferation of pleomorphic neoplastic cells
containing moderate amounts of pigment. The cells
were arranged in haphazard bundles, had a polygonal
to spindle-shaped morphology, mild anisocytosis and
anisokaryosis, and contained a moderate amount of
deep eosinophilic cytoplasm with variably distinct cel-
lular borders. Nuclei varied between round and oval,
and were mostly hyperchromatic with stippled
Figure 4. Histology of the nasal mass in case 2: (a) H&E section
(£40) demonstrating poor cellular differentiation, which in
rare places tended towards spindle cell morphology (black
arrows); (b) positive immunohistochemical labelling for Melan-
A (£40); (c) positive immunohistochemical labelling for vimen-
tin (£40).
278 O. DAVIES ET AL.
chromatin and multiple amphophilic nucleoli. Approxi-
mately one mitotic ﬁgure was evident per high power
ﬁeld (400£). Malignant melanoma, plasma cell tumour
or epithelioid haemangiosarcoma were considered
likely diagnoses based on cellular morphology and the
presence of intracellular pigment. The diagnosis of
melanoma was conﬁrmed with strong positive immu-
nohistochemical labelling with PNL2, S100 and Melan
A (MUM1 negative).
Contrast CT of the head and thorax was performed
for radiotherapy planning and staging of disease under
general anaesthesia. A relatively small soft tissue atten-
uating mass was present in the rostral half of the left
nasal cavity (measuring approximately 2.0 cm rostro-
caudally, 1.7 cm dorsoventrally and 1.1 cm laterome-
dially), with mild involvement of the nasal bone
dorsally and the nasal septum medially (Figure 5). No
metastatic lesions were identiﬁed locoregionally or in
lungs on the CT scan. Cytology of local lymph nodes
was not assessed.
The dog was treated with a hypofractionated radio-
therapy protocol. Planning, set-up and anaesthesia
were as described in case 1. A total dose of 32 Gy was
prescribed to the tumour as four, once-weekly 8 Gy
fractions, using three ﬁelds, consisting of dorsal, right
and left lateral beams; ﬁeld depth was 1.6 cm dorsal,
1.8 cm right lateral and 2.4 cm left lateral, CTV was
0.2 cm around the GTV, and the planning target vol-
ume PTV was 0.4 cm around CTV; eyes and brain were
not included in the treatment ﬁeld. Lymph nodes were
not treated. This treatment was tolerated with minimal
adverse effects; sneezing episodes and minor epistaxis
remained present throughout the treatment protocol.
Repeat CT of the head only was performed 18 days
after the treatment due to reports of persistent epi-
staxis. The CT revealed stable tumour size but with
decreased contrast uptake. At this point, the dog
started therapy with meloxicam (Metacam oral suspen-
sion for dogs, Boehringer Ingelheim, Ingelheim am
Rhein, Germany) at a dose of 0.1 mg/kg BW orally,
once-daily, after which clinical signs (sneezing and epi-
staxis episodes) resolved; the course of meloxicam con-
tinued for approximately six weeks. The dog remained
asymptomatic and repeat CT scan (of the head only)
four months after completion of the treatment
revealed continued stability in tumour size (Figure 5).
Clinical signs recurred 10 months after completion of
hypofractionated radiotherapy treatment. Further
investigation and treatment were declined. The dog
received no further treatment and was lost to follow-
up 12 months after radiation therapy.
3. Discussion
Primary nasal melanoma is described in three dogs. In
all cases, the variable histological appearance of mela-
noma precluded a deﬁnitive histomorphological diag-
nosis (Smith et al. 2002; Choi & Kusewitt 2003; Smedley
et al. 2011). Immunohistochemistry was necessary to
provide the ﬁnal diagnosis in all cases after positive
staining with Melan-A, PNL-2 and vimentin.
Canine intranasal melanoma has been successfully
treated with surgery and radiotherapy once before
(Hicks & Fidel 2006). Radiotherapy is a common pri-
mary treatment for intranasal neoplasia, producing
clinical beneﬁt in over 80% of dogs and a median sur-
vival time (MST) of over 500 days (Fujiwara et al. 2013).
Radiotherapy is also effective in controlling oral mela-
nomas, with an overall response rate of 83% (Bateman
et al. 1994; Proulx et al. 2003) and a MST of 80–
758 days, depending on factors such as tumour stage,
sub-location in the oral cavity and the degree of osteol-
ysis (Freeman et al. 2003; Proulx et al. 2003; Kawabe
et al. 2015). Given its established efﬁcacy, radiotherapy
was performed ﬁrst-line in the dogs in this report; sur-
gery was considered unnecessary since all dogs experi-
enced satisfactory control of disease with radiotherapy.
Fifty-three per cent of oral melanomas have evi-
dence of metastasis at diagnosis (Williams & Packer
2003). Even if local control of the primary tumour has
been effective, most dogs will die of distant metastasis
(Freeman et al. 2003; Proulx et al. 2003). Case 1 did not
have metastasis at diagnosis or follow-up; the tumour’s
low mitotic index may be pertinent in this regard, since
a low mitotic index has been shown to correlate with
indolent behaviour of oral melanomas (Spangler &
Kass 2006; Esplin 2008). The existing report of a canine
intranasal melanoma also describes a low mitotic index
and absence of metastasis (Hicks & Fidel 2006), never-
theless, the short survival of case 1 makes evaluation
of the metastatic propensity of this tumour unreliable.
The metastatic status of case 2 is unknown since the
cause of the dog’s seizures is unclear; metastasis, local
extension of disease and delayed radiation toxicity are
possible aetiologies. It is not possible to comment on
the metastatic status of case 3 since thorough staging
and restaging of disease was declined.
Cases 1 and 3 received hypofractionated radiother-
apy, since no signiﬁcant difference in response and sur-
vival between deﬁnitive and hypofractionated
protocols for canine oral melanoma have been demon-
strated (Proulx et al. 2003). Case 2 received deﬁnitive
radiotherapy, which has been shown to be the most
Figure 5. Pre-treatment and post-treatment CT images of case
3: (a) pre-treatment transverse; (b) post-treatment transverse.
Arrows mark the tumour.
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effective protocol for primary canine intranasal neopla-
sia (Theon et al. 1993; Adams et al. 2005), and was also
judged to be a safer therapy for this dog given the
proximity of the tumour to the brain. Deﬁnitive proto-
cols are more expensive and more likely to cause acute
adverse effects than hypofractionated protocols; case
2 developed a non-healing descemetocele, likely an
acute adverse effect of treatment. Desmetocoele is an
uncommon adverse effect of radiation therapy in dogs;
however, ulcerative keratitis has been reported to
occur in 26% dogs where the orbit is included in the
radiation ﬁeld (Pinard et al. 2012). Due to the location
of this tumour, the dog’s globe received a high dose of
radiation, and since no pre-existing, or previous ocular
disease was reported in this dog, it is considered plau-
sible that ulcerative keratitis was exacerbated by the
use of oral prednisolone and possibly self-trauma by
the patient, resulting in a desmetocoele.
We are unable to comment on differences in the
long-term tumour control between cases 1 and 2, since
case 1 died from unrelated causes ﬁve months after
treatment and the cause of seizures in case 2 remains
undetermined. Nevertheless it is interesting that case 3
demonstrated good control of clinical signs for 10
months before clear signs of disease progression,
despite the documentation of no more than stable dis-
ease on CT follow-up. The low mitotic activity of this
tumour may signify a relatively indolent behaviour in
this case.
Since there is no clear evidence that adjuvant
immunotherapy or cytotoxic chemotherapy is beneﬁ-
cial in canine melanoma (Proulx et al. 2003; Murphy
et al. 2005), none of the dogs in this report received
medical therapy other than a COX-2 inhibitor (in cases
2 and 3). Although the effect of COX-2 inhibition has
not been investigated in canine melanoma, in certain
canine cancers, COX-2 expression correlates with
malignancy and is negatively associated with survival
(Proulx et al. 2003; Martinez et al. 2011).
Melanoma should be considered a rare differential
diagnosis for primary intranasal neoplasia in dogs and
immunohistochemistry is useful for deﬁnitive diagno-
sis. These three cases suggest that radiotherapy alone
can be used to manage this disease.
Acknowledgements
The authors would like to thank Philippa McLaren, Michael
Day, Henny Martineau and Sam Beck, the staff of the Royal
Veterinary College Diagnostic Laboratory Services and Bridge
Pathology Ltd for interpretation of clinical and anatomic
pathology submissions.
Disclosure statement
The authors declare no conﬂicts of interest.
References
Adams WM, Bjorling DE, McAnulty JE, Green EM, Forrest LJ,
Vail DM. 2005. Outcome of accelerated radiotherapy alone
or accelerated radiotherapy followed by exenteration of
the nasal cavity in dogs with intranasal neoplasia: 53 cases
(1990–2002). J Am Vet Med Assoc. 227(6):936–941.
Bateman KE, Catton PA, Pennock PW, Kruth SA. 1994. 0-7-21
Radiation therapy for the treatment of canine oral mela-
noma. J Vet Intern Med. 8(4):267–272.
Busam KJ, Jungbluth AA. 1999. Melan-A, a new melanocytic
differentiation marker. Adv Anat Pathol. 6(1):12–18.
Choi C, Kusewitt DF. 2003. Comparison of tyrosinase-related
protein-2, S-100, and Melan A immunoreactivity in canine
amelanotic melanomas. Vet Pathol. 40(6):713–718.
Esplin DG. 2008. Survival of dogs following surgical excision
of histologically well-differentiated melanocytic neo-
plasms of the mucous membranes of the lips and oral cav-
ity. Vet Pathol. 45:889–896.
Freeman KP, Hahn KA, Harris FD, King GK. 2003. Treatment of
dogs with oral melanoma by hypofractionated radiation
therapy and platinum-based chemotherapy (1987–1997).
J Vet Intern Med. 17(1):96–101.
Fujita M, Takaishi Y, Yasuda D, Hasegawa D, Taniguchi A,
Takahashi K, Orima H. 2008. Intranasal hemangiosarcoma
in a dog. J Vet Med Sci. 70(5):525–528.
Fujiwara A, Kobayashi T, Kazato Y, Yayoshi N, Fujita M. 2013.
Efﬁcacy of hypofractionated radiotherapy for nasal
tumours in 38 dogs (2005–2008). J Small Anim Pract. 54
(2):80–86.
Giudice C, Ceciliani F, Rondena M, Stefanello D, Grieco V.
2010. Immunohistochemical investigation of PNL2 reactiv-
ity of canine melanocytic neoplasms and comparison with
Melan A. J Vet Diagn Invest. 22:389–394.
Gouldesbrough D, Martin-Hirsch D, Lannigan F. 1992. Intrana-
sal malignant melanoma arising in an inverted papilloma.
Histopathology. 20:523–526.
Hicks DG, Fidel JL. 2006. Intranasal malignant melanoma in a
dog. J Am Anim Hosp Assoc. 42(6):472–476.
Kawabe M, Mori T, Ito Y, Murakami M, Sakai H, Yanai T, Maruo
K. 2015. Outcomes of dogs undergoing radiotherapy for
treatment of oral malignant melanoma : 111 cases (2006–
2012). J Am Vet Med Assoc. 247(10):1146–1153.
Koenig A, Wojcieszyn J, Weeks BR, Modiano JF. 2001. Expres-
sion of S100a, vimentin, NSE, and melan A/MART-1 in seven
canine melanoma cells lines and twenty-nine retrospective
cases of canine melanoma. Vet Pathol. 38:427–435.
Kubicek L, Milner R, An Q, Kow K, Chang M, Cooke K, Fox L,
Farese J, Bacon N, Lurie D. 2016. Outcomes and prognostic
factors associated with canine sinonasal tumors treated
with curative intent cone-based stereotactic radiosurgery
(1999–2013). Vet Radiol Ultrasound. 57(3):331–340.
Lana SE, Dernell WS, Lafferty MH, Withrow SJ, LaRue SM.
2004. Use of radiation and a slow-release cisplatin formu-
lation for treatment of canine nasal tumors. Vet Radiol
Ultrasound. 45(6):577–581.
Lawrence JA, Forrest LJ, Turek MM, Miller PE, Mackie TR, Jara-
dat HA, Vail DM, Dubielzig RR, Chappell R, Mehta MP.
2010. Proof of principle of ocular sparing in dogs with
sinonasal tumors treated with intensity-modulated radia-
tion therapy. Vet Radiol Ultrasound. 51(5):561–570.
Lin C, Yang S, Lai C. 2003. Primary malignant melanoma of
the nasal cavity. Chang Gung Med J. 26(11):857–862.
Madewell B, Priester W, Gillette E. 1976. Neoplasms of the
nasal passages and paranasal sinuses in domesticated ani-
mals as reported by 13 veterinary colleges. Am J Vet Res.
37(7):851–856.
280 O. DAVIES ET AL.
Martinez CM, Penaﬁel-Verdu C, Vilafranca M, Ramirez G, Men-
dez-Gallego M, Buendia, AJ, Sanchez J. 2011. Cyclooxy-
genase-2 expression is related with localization,
proliferation, and overall survival in canine melanocytic
neoplasms. Vet Pathol. 48(6):1204–1211.
Millanta F, Fratini F, Corazza M, Castagnaro M, Zappulli V, Poli
A. 2002. Proliferation activity in oral and cutaneous canine
melanocytic tumours: Correlation with histological param-
eters, location, and clinical behaviour. Res Vet Sci. 73
(1):45–51.
Morris JS, Dunn JK, Dobson JM, White RAS. 1994. Effects of
radiotherapy alone and surgery and radiotherapy on sur-
vival of dogs with nasal tumours. J Small Anim Pract. 35
(11):567–573.
Murphy S, Hayes AM, Blackwood L, Maglennon G, Pattinson H,
Sparkes AH. 2005. Oral malignant melanoma – the effect of
coarse fractionation radiotherapy alone or with adjuvant
carboplatin therapy. Vet Comp Oncol. 3(4):222–229.
Naganobu K, Ogawa H, Uchida K, Yamaguchi R, Ohashi F,
Kubo K, Aoki M, Kuwamura M, Ogawa Y, Matsuyama K.
2000. Mast cell tumour in the nasal cavity of a dog. J Vet
Med Sci. 62(9):1009–1011.
Papazoglou LG, Koutinas AF, Plevraki AG, Tontis D. 2001. Pri-
mary intranasal transmissible venereal tumour in the dog:
a retrospective study of six spontaneous cases. J Vet Med
A. 48(7):391–400.
Patnaik A. 1989. Canine sinonasal neoplasms: clinicopathologi-
cal study of 285 cases. J Am Anim Hosp Assoc. 25:103–114.
Peryaga G, Lafond C, Pointreau Y, Giraud P, Maingon P. 2016.
Nasal cavity and paransal sinus cancer. Cancer Radiother.
20:S99–103.
Pinard CL, Mutsaers AJ, Mayer MN, Paul Woods J. 2012. Retro-
spective study and review of ocular radiation side effects
following external-beam Cobalt-60 radiation therapy in 37
dogs and 12 cats. Can Vet J. 53(12):1301–1307.
Proulx DR, Ruslander DM, Dodge RK, Hauck ML. 2003. A retro-
spective analysis of 140 dogs with oral melanoma treated
with external beam radiation. Vet Radiol Ultrasound. 44
(3):352–359.
Rabanal R, Fondevila DM, Montane V, Domingo M, Ferrer L.
1989. Immunocytochemical diagnosis of skin tumours of
the dog with special reference to undifferentiated types.
Res Vet Sci. 47(1):129–133.
Ramos-Vara JA, Beissenherz ME, Miller MA, Johnson GC, Pace
LW, Fard A, Kottler SJ. 2000. Retrospective study of 338
canine oral melanomas with clinical, histologic, and
immunohistochemical review of 129 cases. Vet Pathol. 37
(6):597–608.
Ramos-Vara JA, Miller MA. 2011. Immunohistochemical iden-
tiﬁcation of canine melanocytic neoplasms with antibod-
ies to melanocytic antigen PNL2 and tyrosinase:
comparison with Melan A. Vet Pathol. 48:443–450.
Smedley RC, Spangler WL, Esplin DG, Kitchell BE, Bergman PJ,
Ho HY, Bergin IL, Kiupel M. 2011. Prognostic markers for
canine melanocytic neoplasms: a comparative review of
the literature and goals for future investigation. Vet
Pathol. 48(1):54–72.
Smith SH, Goldschmidt MH, McManus PM. 2002. A compara-
tive review of melanocytic neoplasms. Vet Pathol. 39
(6):651–678.
Spangler WL, Kass PH. 2006. The histologic and epidemio-
logic bases for prognostic considerations in canine mela-
nocytic neoplasia. Vet Pathol. 43(2):136–149.
Theon A, Madewell BR, Harb MF, Dungworth DL. 1993. Mega-
voltage irradiation of neoplasms of the nasal and para-
nasal cavities in 77 dogs. J Am Vet Med Assoc. 202
(9):1469–1475.
Tuohy JL, Selmic LE, Worley DR, Ehrhart NP, Withrow SJ. 2014.
Outcome following curative-intent surgery for oral mela-
noma in dogs : 70 cases (1998–2011). J Am Vet Med Assoc.
245(11):1266–1273.
Ueno H, Kobayashi Y, Yamada K. 2007. Olfactory esthesio-
neuroblastoma treated with orthovoltage radiotherapy in
a dog. Aust Vet J. 85(7):271–275.
Williams LE, Packer RA. 2003. Association between lymph
node size and metastasis in dogs with oral malignant mel-
anoma: 100 cases (1987–2001). J Am Vet Med Assoc. 222
(9):1234–1236.
VETERINARY QUARTERLY 281
